Insider trade

CFO exercised or converted 188 CYTK derivative securities

Traded Jun 24, 2026 · Filed Jun 29, 2026

CytokineticsCYTK

188
Derivative units

Why it stands out

Derivative exercise or conversion — not an open-market buy.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Jun 24, 2026
Reporting period: Not applicable
Filed with the SEC: Jun 29, 2026

CFOOption exercise

Context

Classification

option exercise

Code M — exercise or conversion of a derivative security

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001061983-26-000071

Filed / recorded

Jun 29, 2026, 10:05 PM UTC

Added to OQRO

Oct 6, 2026, 7:14 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

CYTOKINETICS INC

Issuer CIK

1061983

Ticker

CYTK

Reporting person

Sung Lee

Relationship

Officer

Officer title

EVP, Chief Financial Officer

Security

Incentive Stock Option (Right to Buy)

Table

Derivative (Table II)

Transaction date

Jun 24, 2026

Transaction code

M

Shares / units

188

Price per share

$0.00

Acquired / disposed

Disposed (D)

Shares owned after

6,011

Ownership form

Direct

Amendment

No

Around the same time

Robert I BlumPresident & CEO

Filed 2mo ago

7,500Shares · @ $10.60

Traded Jul 27 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record

Robert I Blum (President & CEO) sold ~$607K of Cytokinetics

Planned saleFiled 2mo ago

Robert I BlumPresident & CEO

Filed 2mo ago

7,500Derivative units

Traded Jul 27 · filed the same day

Derivative exercise or conversion — not an open-market buy.

More Official record